LOS ANGELES, Calif., July 29, 2015 (GLOBE NEWSWIRE) -- Equites.com, an interactive online community for financial publication, today published a Video Interview with Dr. Daniel Teper, CEO of Immune Pharmaceuticals, Inc. (NASDAQ:IMNP).
Immune Pharmaceuticals secured today funding of up to $21.5 Million from institutional investors, $12 Million in Equity Financing and up to $9.5 Million in Debt Financing. Company to Advance its Immuno-Dermatology and Inflammatory Bowel Disease Product CandidatesLead Compound Bertilimumab, First-in-Class Autoimmune Therapy, a Priority.
(see here: http://immunepharmaceuticals.com/).
Click the following link to watch the video interview on EQUITES.COM
Please review important disclosures on our website at: EQUITES.COM
About Immune Pharmaceuticals
Immune Pharmaceuticals Inc. applies a personalized approach to treating and, developing novel, highly-targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. The Company's lead product candidate, bertilimumab, is in clinical development for moderate to severe ulcerative colitis as well as for bullous pemphigoid, an orphan auto-immune dermatological condition. Immune's pipeline also includes NanomAbs®, antibody nanoparticle conjugates, for the targeted delivery of chemotherapeutics, and AmiKet™, a topical neuropathic pain drug candidate.
For more information, visit Immune's website at www.immunepharmaceuticals.com
About Equites.com
Equities.com is an online financial news organization and social community for self-directed investors, public and private companies, market experts, and professional service providers across the global capital markets. The Equities.com Issuer Dashboard is an ideal platform to effectively manage corporate communication and investor awareness campaigns, engage with market intermediaries and financial advisors, and research industry peers. Registered members can leverage our market-leading commentary and content curation, as well as our proprietary research tools. Go to http://www.equities.com/community/register to become a member.